Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Pfizer Inc (PFE) Price & Performance

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Pfizer Inc — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.6, while Pfizer Inc trades at $27.9 (market cap $158.39B). The key difference: Pfizer Inc pays a 6.19% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.

PDBCPFE
52-Week High
$19.60$29.02
52-Week Low
$13.16$23.60
Market Cap
$158.39B
Volume
29,869,932
Sector
Health
Enterprise Value
$209.89B
Dividend Yield
6.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF

PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.30, up 1.53% with a bullish technical signal from moving averages. Recent institutional buying from Concurrent Investment Advisors and Geneos Wealth Management signals confidence, though oscillators show bearish momentum with RSI levels indicating potential overbought conditions. The fund has delivered strong returns, outperforming the S&P 500 by nearly 10 percentage points since March 2024.

Commodity momentum faces headwinds despite geopolitical tensions, with a Seeking Alpha downgrade to hold citing weakening technicals. The fund offers defensive exposure amid market shifts away from tech, but investors face risks from potential commodity price volatility and Middle East conflict impacts on oil markets.

Pfizer Inc

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF

The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.

Read more on PDBC

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE